NP03, a novel low-dose lithium formulation, is neuroprotective in the YAC128 mouse model of Huntington disease

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 282-289

  Pouladi, Mahmoud A ^a,b   Brillaud, Elsa ^c   Xie, Yuanyun ^a   Conforti, Paola ^d   Graham, Rona K ^a   Ehrnhoefer, Dagmar E ^a   Franciosi, Sonia ^a   Zhang, Weining ^a   Poucheret, Patrick ^e   Compte, Elsa ^c   Maurel, Jean Claude ^c   Zuccato, Chiara ^d   Cattaneo, Elena ^d   Néri, Christian ^f,g,h   Hayden, Michael R ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c Medesis Pharma   (France)

^d UNIVERSITY OF MILAN   (Italy)

^e UMR QUALISUD   (France)

^f INSERM   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

^h HENRI MONDOR HOSPITAL   (France)

Author keywords

BDNF; Caspase 6; GSK 3; Huntington disease; Lithium; Tau; Transgenic mouse model

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CASPASE 6; LITHIUM SALT; MESSENGER RNA; NEUROPROTECTIVE AGENT; NP 03; PHOSPHOPROTEIN DARPP 32; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN SIZE; BRAIN TISSUE; CELL COUNT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVATION; FEMALE; HUNTINGTON CHOREA; LOW DRUG DOSE; MALE; MICROEMULSION; MOTOR PERFORMANCE; MOUSE; NERVE CELL; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ROTAROD TEST; TESTIS ATROPHY; TREATMENT DURATION;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; HUNTINGTON DISEASE; IMMUNOBLOTTING; LITHIUM; MALE; MICE; MOTOR ACTIVITY; NEUROPROTECTIVE AGENTS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84866612250     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.06.026     Document Type: Article

References (45)

1. Arrasate M., et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death. Nature 2004, 431:805-810.
2. Bates G., et al. Huntington's disease 2002, Oxford University Press, Oxford; New York.
3. Berger Z., et al. Lithium rescues toxicity of aggregate-prone proteins in Drosophila by perturbing Wnt pathway. Hum. Mol. Genet. 2005, 14:3003-3011.
4. Carmichael J., et al. Glycogen synthase kinase-3beta inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation. J. Biol. Chem. 2002, 277:33791-33798.
5. Chalecka-Franaszek E., Chuang D.M. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:8745-8750.
6. Chiu C.T., et al. Combined treatment with the mood stabilizers lithium and valproate produces multiple beneficial effects in transgenic mouse models of Huntington's disease. Neuropsychopharmacology 2011, 36:2406-2421.
7. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3:479-487.
8. Conforti P., et al. Blood level of brain-derived neurotrophic factor mRNA is progressively reduced in rodent models of Huntington's disease: restoration by the neuroprotective compound CEP-1347. Mol. Cell. Neurosci. 2008, 39:1-7.
9. Datta S.R., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997, 91:231-241.
10. Dudek H., et al. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science 1997, 275:661-665.
11. Gharami K., et al. Brain-derived neurotrophic factor over-expression in the forebrain ameliorates Huntington's disease phenotypes in mice. J. Neurochem. 2008, 105:369-379.
12. Gil-Mohapel J.M. Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice. CNS Neurosci. Ther. 2012, 18:77-86.
13. Graham R.K., et al. Cleavage at the caspase-6 site is required for neuronal dysfunction and degeneration due to mutant huntingtin. Cell 2006, 125:1179-1191.
14. Graham R.K., et al. Proteolysis at the caspase-6 site of mutant huntingtin influences caspase-6 activation in vivo. J. Neurosci. 2010, 30:15019-15029.
15. Grünfeld J.-P., Rossier B.C. Lithium nephrotoxicity revisited. Nat. Rev. Nephrol. 2009, 5:270-276.
16. Harper S.Q., et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5820-5825.
17. Hong M., et al. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J. Biol. Chem. 1997, 272:25326-25332.
18. Jeong H., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
19. Jordà E.G., et al. Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 2005, 134:1001-1011.
20. Marmol F. Lithium: bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1761-1771.
21. Milnerwood A.J., et al. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in huntington's disease mice. Neuron 2010, 65:178-190.
22. Nikolaev A., et al. APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 2009, 457:981-989.
23. Okamoto S., et al. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat. Med. 2009, 15:1407-1413.
24. Park K.J., et al. p75NTR-dependent, myelin-mediated axonal degeneration regulates neural connectivity in the adult brain. Nat. Neurosci. 2010, 13:559-566.
25. Phiel C.J., et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003, 423:435-439.
26. Pouladi M.A., et al. Prevention of depressive behaviour in the YAC128 mouse model of Huntington disease by mutation at residue 586 of huntingtin. Brain 2009, 132:919-932.
27. Pouladi M.A., et al. Marked differences in neurochemistry and aggregates despite similar behavioural and neuropathological features of Huntington disease in the full-length BACHD and YAC128 mice. Hum. Mol. Genet. 2012, 21:2219-2232.
28. Ravikumar B., et al. Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat. Genet. 2004, 36:585-595.
29. Rouaux C., et al. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration. EMBO J. 2003, 22:6537-6549.
30. Sarkar S., et al. Lithium induces autophagy by inhibiting inositol monophosphatase. J. Cell Biol. 2005, 170:1101-1111.
31. Slow E.J., et al. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 2003, 12:1555-1567.
32. Tallaksen-Greene S.J., Albin R.L. Treating mouse models of Huntington disease. Neuropsychopharmacol. Off. Publ. Am. Coll. Neuropsychopharmacol. 2011, 36:2373-2374.
33. Tang Z., et al. Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3beta phosphorylation. J. Exp. Med. 2010, 207:867-880.
34. Tsvetkov A.S., et al. A small-molecule scaffold induces autophagy in primary neurons and protects against toxicity in a Huntington disease model. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:16982-16987.
35. Van Raamsdonk J.M., et al. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J. Neurosci. 2005, 25:4169-4180.
36. Van Raamsdonk J.M., et al. Testicular degeneration in Huntington disease. Neurobiol. Dis. 2007, 26:512-520.
37. Voisine C., et al. Identification of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS One 2007, 2:e504.
38. Watase K., et al. Lithium therapy improves neurological function and hippocampal dendritic arborization in a spinocerebellar ataxia type 1 mouse model. PLoS Med. 2007, 4:e182.
39. Wei H., et al. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001, 106:603-612.
40. Weiss A., et al. Single-step detection of mutant huntingtin in animal and human tissues: a bioassay for Huntington's disease. Anal. Biochem. 2009, 395:8-15.
41. Wood N.I., Morton A.J. Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res. Bull. 2003, 61:375-383.
42. Xie Y., et al. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J. Neurosci. 2010, 30:14708-14718.
43. Yasuda S., et al. The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol. Psychiatry 2009, 14:51-59.
44. Zuccato C., et al. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat. Genet. 2003, 35:76-83.
45. Zuccato C., et al. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol. Rev. 2010, 90:905-981.